KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) EBIT Margin (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed EBIT Margin for 11 consecutive years, with 969.84% as the latest value for Q1 2025.

  • On a quarterly basis, EBIT Margin changed N/A to 969.84% in Q1 2025 year-over-year; TTM through Dec 2025 was 689.79%, a N/A change, with the full-year FY2025 number at 689.79%, changed N/A from a year prior.
  • EBIT Margin was 969.84% for Q1 2025 at Xenon Pharmaceuticals, up from 28884.85% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 879.18% in Q4 2021 to a low of 28884.85% in Q3 2022.
  • A 3-year average of 4569.86% and a median of 669.17% in 2021 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: skyrocketed 113011bps in 2021, then crashed -2853823bps in 2022.
  • Xenon Pharmaceuticals' EBIT Margin stood at 879.18% in 2021, then crashed by -3385bps to 28884.85% in 2022, then soared by 97bps to 969.84% in 2025.
  • Per Business Quant, the three most recent readings for XENE's EBIT Margin are 969.84% (Q1 2025), 28884.85% (Q3 2022), and 5655.78% (Q2 2022).